Investor Relations
Skip to content
ViruCure
  • Home
  • About
    • Our Story
    • Team
  • Products
    • Our Products
    • Product Pipeline
  • NADAV Technology
  • Clinical
    • Phase 1/2
    • Preclinical
    • Publications
  • News
  • Contact
ViruCure
  • Home
  • About
    • Our Story
    • Team
  • Products
    • Our Products
    • Product Pipeline
  • NADAV Technology
  • Clinical
    • Phase 1/2
    • Preclinical
    • Publications
  • News
  • Contact

news

Join ViruCure at the Immuno Oncology Summit Europe 2018, 27-31 August, Boston, USA

June 28, 2018August 2, 2018

Powering next generation targeted immunotherapies, come and meet with our CTO, Shay Tayeb, and learn more about NADAV – our novel oncolytic virus platform technology.

Learn More
Categories news

ViruCure to attend the Armed Oncolytic Immunotherapies Summit Europe 2018, 26-28 June, Frankfurt, Germany

June 20, 2018August 2, 2018

Meet with our CTO, Shay Tayeb, at the leading end-to-end meeting focused on the next generation of oncolytic virus therapies and discover more about ViruCure’s oncolytic virus technology, NADAV.

Learn More
Categories news

ViruCure to attend the Biotechnology Innovation Organization, 4-7 June, Boston, USA

May 31, 2018August 2, 2018

Come and meet with our CEO & Co-founder, Yoram Drucker at BIO 2018 to learn more about ViruCure’s breakthrough NADAV technology to fight cancer.

Learn More
Categories news

Recent Posts

  • Join ViruCure at the Immuno Oncology Summit Europe 2018, 27-31 August, Boston, USA
  • ViruCure to attend the Armed Oncolytic Immunotherapies Summit Europe 2018, 26-28 June, Frankfurt, Germany
  • ViruCure to attend the Biotechnology Innovation Organization, 4-7 June, Boston, USA

Recent Comments

    Archives

    • June 2018
    • May 2018

    Categories

    • news

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Contact Us

    info@virucure.com

    Linkedin

    ViruCure Therapeutics

    ViruCure Therapeutics is a biotech company that is developing an oncolytic-virus-based technology platform, NADAV, for the targeted treatment of a wide range of cancers.

    © 2018 • ViruCure